Cargando…

Autoimmune Cytopenias Developing Late Post Alemtuzumab-Based Allogeneic Stem Cell Transplantation: Presentation of Short Case Series from a Transplant Center

Stem cell transplantation remains the curative option for many patients with hematological malignancies. The long-term effects of these treatments on the patients and their immune systems have been extensively investigated, but there remains a paucity of data regarding autoimmune manifestations post...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lloyd, Rebecca, Nikolousis, Emmanouil, Kishore, Bhuvan, Lovell, Richard, Shankara, Paneesha, Zeid, Nervana Abou, Horgan, Claire, Panteliadou, Alkistis Kyra, McIlroy, Graham, Xenou, Evgenia, Kaparou, Maria, Holder, Kathleen, Murthy, Vidhya, Kanellopoulos, Alexandros
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2020
Materias:	Case Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7784502/ https://www.ncbi.nlm.nih.gov/pubmed/32806929 http://dx.doi.org/10.1177/0963689720950641

Ejemplares similares

A unique case of durable complete remission after salvage with azacitidine and DLI for high risk flt-3 positive acute myeloid leukemia, following relapse 18 months post allogeneic stem cell transplant
por: Horgan, Claire, et al.
Publicado: (2019)

ERRATUM: A unique case of durable complete remission after salvage with azacitidine and DLI for high risk flt-3 positive acute myeloid leukemia, following relapse 18 months post allogeneic stem cell transplant
por: Horgan, Claire, et al.
Publicado: (2020)

First case of near haploid philadelphia negative B-Cell acute lymphoblastic leukaemia relapsing as acute myeloid leukemia following allogeneic hematopoietic stem cell transplantation
por: Horgan, Claire, et al.
Publicado: (2020)

Management of Allogeneic Stem Cell Transplantation for High-Risk AML following SARS-CoV-2 Associated Pancytopenia with Marked Bone Marrow Biopsy Alterations
por: Kaparou, Maria, et al.
Publicado: (2021)

Reduced Intensity Allogeneic Stem Cell Transplant for Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm
por: Lokare, Anand, et al.
Publicado: (2014)

Cytopenias in Transplant Patients
por: Barry, Maura, et al.
Publicado: (2018)

Alemtuzumab induction in pediatric kidney transplantation
por: Kaabak, Michael M, et al.
Publicado: (2013)

Longitudinal Evaluation of Cytopenias in the Renal Transplant Population
por: Johnson, Aileen C., et al.
Publicado: (2022)

Autoimmune Cytopenias in Pediatric Hematopoietic Cell Transplant Patients
por: Neely, Jessica A., et al.
Publicado: (2019)

Alemtuzumab induction therapy in solid organ transplantation
por: Friend, Peter J
Publicado: (2013)

Cytopenia Occurrence in Kidney Transplant Recipients Within Early Post-transplant Period
por: Jafari, Atefeh, et al.
Publicado: (2017)

Drug-Induced Hematological Cytopenia in Kidney Transplantation and the Challenges It Poses for Kidney Transplant Physicians
por: Khalil, Muhammad Abdul Mabood, et al.
Publicado: (2018)

The evolving role of alemtuzumab (Campath-1H) in renal transplantation
por: Pham, Phuong-Thu T, et al.
Publicado: (2009)

Rescue treatment with eltrombopag in refractory cytopenias after allogeneic stem cell transplantation
por: Aydin, Semra, et al.
Publicado: (2020)

Review of the Clinical Pharmacokinetics and Pharmacodynamics of Alemtuzumab and Its Use in Kidney Transplantation
por: van der Zwan, Marieke, et al.
Publicado: (2017)

An Association between BK Virus Replication in Bone Marrow and Cytopenia in Kidney-Transplant Recipients
por: Pambrun, Emilie, et al.
Publicado: (2014)

Treatment and response of autoimmune cytopenia occurring after allogeneic hematopoietic cell transplantation in children
por: Hwang-Bo, Seok, et al.
Publicado: (2017)

Pharmacokinetics and clinical activity of very low-dose alemtuzumab in transplantation for acute leukemia
por: Spyridonidis, A, et al.
Publicado: (2011)

Alemtuzumab Plus Cyclosporine Treatment of the Autoimmune Hemolytic Anemia in an Adult Bowel Transplant
por: Lauro, A., et al.
Publicado: (2014)

Alemtuzumab
por: Tridente, Giuseppe
Publicado: (2013)

Differential expression of circulating miRNAs after alemtuzumab induction therapy in lung transplantation
por: Benazzo, A., et al.
Publicado: (2022)

Induction Strategies in Lung Transplantation: Alemtuzumab vs. Basiliximab a Single-Center Experience
por: Furukawa, Masashi, et al.
Publicado: (2022)

A Decade of Experience With Alemtuzumab Therapy for Severe or Glucocorticoid-Resistant Kidney Transplant Rejection
por: van Vugt, Lukas K., et al.
Publicado: (2023)

Long-term immunosuppression and multiple transplants predispose systemic lupus erythematosus patients with cytopenias to hematologic malignancies
por: Lanjewar, Sonali, et al.
Publicado: (2021)

B-cell depletion abrogates immune mediated cytopenia and rejection of cord blood transplantation in Hurler syndrome
por: Nataraj, R., et al.
Publicado: (2021)

Autoimmune Cytopenias Post Hematopoietic Stem Cell Transplantation in Pediatric Patients With Osteopetrosis and Other Nonmalignant Diseases
por: Even-Or, Ehud, et al.
Publicado: (2022)

Alemtuzumab Induction and Delayed Acute Rejection in Steroid-Free Simultaneous Pancreas-Kidney Transplant Recipients
por: Bank, Jonna R., et al.
Publicado: (2016)

Alemtuzumab as a Therapy for Chronic Lung Allograft Dysfunction in Lung Transplant Recipients With Short Telomeres
por: Trindade, Anil J., et al.
Publicado: (2020)

Low-dose alemtuzumab induction in a tailored immunosuppression protocol for sensitized kidney transplant recipients
por: Guthoff, Martina, et al.
Publicado: (2020)

Safety of Alemtuzumab and Autologous Hematopoietic Stem Cell Transplantation Compared to Noninduction Therapies for Multiple Sclerosis
por: Alping, Peter, et al.
Publicado: (2021)

Thymoglobulin Versus Alemtuzumab Versus Basiliximab Kidney Transplantation From Donors After Circulatory Death
por: Asderakis, Argiris, et al.
Publicado: (2022)

Campylobacter Jejuni and Cytopenias
por: Schattner, Ami
Publicado: (2013)

Risk Factors and Outcomes of Klebsiella pneumoniae Infection Before and After Allogeneic Hematopoietic Cell Transplantation
por: Gavriilaki, Eleni, et al.
Publicado: (2021)

Population Pharmacokinetics of Alemtuzumab (Campath) in Pediatric Hematopoietic Cell Transplantation: Towards Individualized Dosing to Improve Outcome
por: Admiraal, Rick, et al.
Publicado: (2019)

Guillain-Barré syndrome and chronic inflammatory demyelinating polyradiculoneuropathy after alemtuzumab therapy in kidney transplant recipients
por: van der Zwan, Marieke, et al.
Publicado: (2020)

Autologous haematopoietic stem cell transplantation compared with alemtuzumab for relapsing–remitting multiple sclerosis: an observational study
por: Zhukovsky, Christina, et al.
Publicado: (2021)

Haploidentical Stem Cell Transplantation Using Post-Transplant Cyclophosphamide for T-Cell Prolymphocytic Leukemia after Alemtuzumab Induction Therapy: A Case Report
por: Okada, Naoki, et al.
Publicado: (2023)

Cytopenia in adult brucellosis patients
por: Kaya, Safak, et al.
Publicado: (2018)

Cytopenia associated with copper deficiency
por: Uchino, Kaori, et al.
Publicado: (2021)

A comparative study of reduced dose alemtuzumab in matched unrelated donor and related donor reduced intensity transplants
por: Jardine, Laura, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_d1rcge66t4mr2803vmb2qq8pgh